Last reviewed · How we verify
NCT07250360
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
trial testing Adjuvant chemotheapy in Non-small Cell Lung Cancer Stage I in 2,072 participants. Completed in 1 June 2025.
31 December 2019
Quick facts
| Lead sponsor | The First Affiliated Hospital with Nanjing Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,072 |
| Start date | 1 January 2015 |
| Primary completion | 31 December 2019 |
| Estimated completion | 1 June 2025 |
Drugs / interventions tested
- Adjuvant chemotheapy — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer Stage I — all drugs for Non-small Cell Lung Cancer Stage I →
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Who can join
Adults 18 to 85, any sex, with Non-small Cell Lung Cancer Stage I. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Brief Summary The goal of this clinical trial is to evaluate the effect of postoperative adjuvant chemotherapy (ACT) in patients with stage I non-squamous non-small cell lung cancer (NSCLC) after curative resection. The main questions it aims to answer are: Does ACT improve recurrence-free survival (RFS) compared with observation alone? Does ACT provide disease-free survival (DFS) benefit in this patient population? Researchers will compare the adjuvant chemotherapy group with the observation group to see if chemotherapy reduces the risk of recurrence and improves survival outcomes. Participants will: Receive standard platinum-based adjuvant chemotherapy after surgery or undergo regular postoperative surveillance according to institutional guidelines. Be followed at scheduled intervals with clinical assessments and imaging to monitor for recurrence and survival outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07250360
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Adjuvant chemotheapy
Trials testing the same drug.
- NCT02318095 — Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer · NA · completed
Other recruiting trials for Non-small Cell Lung Cancer Stage I
Currently open trials in the same condition.
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT05453721 — Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Metho · NA · recruiting
- NCT04585477 — Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) · Phase 2 · recruiting
Other The First Affiliated Hospital with Nanjing Medical University trials
Trials by the same sponsor.
- NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
- NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
- NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
- NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07250360 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
- Last refreshed: 26 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07250360.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing